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Recent clinical trial evidence supports an inflammatory etiology in acute ischemic heart
disease. When a segment of coronary artery becomes inflamed, important cytokines, such as
tissue factor, are released, facilitating thrombosis. Serum inflammatory markers are elevated
in most acute coronary syndrome patients at presentation. Mortality risk has been shown to
be associated with increased levels of high-sensitivity C-reactive protein (CRP), interleukin
6, and serum vascular cell adhesion molecule. Platelets, which are rich in inflammatory
mediators (CD40 and its ligand thrombospondin, and phospholipase A2), also supply
important triggers for the inflammatory cascade. In addition, more than 35 platelet-associated
messenger ribonucleic acid mediators involved in arterial injury and inflammation have been
found. The use of biomarkers of inflammation, such as CRP, and of the sequelae of
embolization, such as troponin, provide a window into the underlying pathophysiology of
acute ischemic heart disease. New agents from three distinct drug classes have recently
flooded the therapeutic armamentarium. Decision-making is further complicated by the
choice of an invasive (aggressive) or a medical (conservative) strategy of management with
respect to coronary revascularization. For patients at highest risk, aspirin, beta-blockers,
nitrates, and a statin should be given, and clopidogrel, enoxaparin, a glycoprotein (GP)
IIb/IIIa inhibitor, plus an invasive strategy should be considered. For intermediate- and
low-risk patients, a “sliding-scale” approach may be best. Decisions about the three classes of
antithrombotics—low-molecular-weight heparins, GP IIb/IIIa inhibitors, and thienopyri-
dines—along with whether to adopt an early invasive strategy, should be made on an
individual basis. (J Am Coll Cardiol 2003;41:123S–129S) © 2003 by the American College
of Cardiology Foundation
Evidence from recent clinical trials and mechanistic studies
underline the importance of an inflammatory etiology in
acute ischemic heart disease. While there are many ac-
knowledged risk factors (hypercholesterolemia, smoking,
obesity, diabetes, homocysteinemia, and many others), their
final common pathway appears to involve the inducement of
an arterial inflammatory state. Arterial plaques that are low
in collagen but rich in matrix metalloproteinases and mono-
nuclear cells are particularly vulnerable. When a segment of
coronary artery becomes inflamed, important cytokines,
such as tissue factor, are released, and thrombosis is greatly
facilitated.
While the inflammation hypothesis for the pathogenesis
of acute ischemic heart disease is not new (1), its acceptance
has grown substantially. At the same time, the availability of
multiple new agents from three distinct drug classes has
virtually flooded the therapeutic armamentarium. The de-
cision whether coronary revascularization should be per-
formed, and when, is further complicated by the need to
choose an invasive/aggressive or a medical/conservative
strategy of management. In a sense, this has transformed the
therapeutic landscape of acute coronary syndrome (ACS)
into an “acute confusional state,” given the wide variety of
choices for clinicians and the minimal evidence for rational
and integrated use of the entire array of therapeutic ap-
proaches.
This review will highlight the key principles that we have
come to accept regarding the underlying pathophysiology of
ACS, and attempt to link these principles with particular
therapeutic options. In so doing, the goal will be to create a
framework for a unifying approach to treatment.
Inflammation and embolization. Multiple sites of the
coronary arteries may be involved in a smoldering, chronic
inflammatory state (Fig. 1). There appears to be consider-
able interpatient and interlesion variability with respect to
the extent of the inflammatory atherosclerotic process.
Serum inflammatory markers, however, are elevated in most
ACS patients at presentation. The risk of subsequent
fatality has been shown to be associated with increased levels
of high-sensitivity C-reactive protein (hs-CRP), interleukin
6 (IL-6), and serum vascular cell adhesion molecule
(VCAM) (2–4).
Although we commonly consider white blood cells to be
the principal mediators of inflammation, the pivotal role of
platelets has recently been demonstrated (5,6). Despite
being enucleated, platelets are rich in inflammatory media-
tors, including the CD40 receptor and CD40 ligand throm-
bospondin and phospholipase A2 (5,6). Recent work by
Lindemann et al. (6) has demonstrated the important
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contribution of platelet-derived messenger ribonucleic acid
(mRNA); more than 35 platelet-associated mRNA media-
tors involved in arterial injury and inflammation have been
found (6). Originally, the CD40 receptor and ligand were
believed to be predominantly T-cell lymphocyte-derived,
but data from recent studies indicate that at least 90% of
CD40 ligand in the body is derived from platelets. Further-
more, the CD40 receptor and ligand are among the most
important triggers of the cascade of inflammatory cytokines
and adhesion molecules, with rapid induction of the expres-
sion of VCAM, intercellular adhesion molecules, and mul-
tiple potent inflammatory mediators (7).
Along with our enhanced understanding of the expanded
role of platelets, we have also learned about the propensity
of atherosclerotic plaque to embolize. This occurs sponta-
neously, as evidenced by the occurrence of circulating
endothelial cells (8), but also when the artery is directly
manipulated via balloon angioplasty, stenting, or other
endovascular therapeutic techniques. The embolization is
apt to be comprised of microparticulate atheromatous ma-
terial, as has been routinely demonstrated through the use of
emboli capture devices (9). The embolus may or may not
contain platelet thrombus. However, a key response to the
showering of debris into the microvasculature will be plate-
let activation and aggregation (10). Microvascular obstruc-
tion leads to ischemic cell death and the development of
troponin positivity. Thus, the use of biomarkers of inflam-
mation such as CRP, and of the sequelae of embolization
such as troponin, provides a window into the underlying
pathophysiology of acute ischemic heart disease.
Using troponin to guide therapy. It is clear that clinical
and electrocardiographic criteria are insufficient to deter-
mine risk in patients with ACS. For example, using data
from a large cohort of over 290,000 patients, Welch et al.
(11) found a 5.7% death rate by day 7 in patients with a
normal electrocardiogram on presentation (Fig. 2). There is
now abundant evidence linking elevated levels of the im-
portant cardiovascular biomarker troponin (specifically tro-
ponin I or T) with adverse major cardiovascular events,
including an overall fourfold increased risk of fatality in an
aggregate of 13 series (12) (Fig. 3). Beyond elevated risk,
several studies have confirmed the specific value of low-
molecular-weight heparin (LMWH) (13,14) or small mol-
ecule platelet glycoprotein (GP) IIb/IIIa inhibitors (15,16)
in troponin-positive patients (Fig. 4). Recently, the use of
invasive strategies, specifically angiography and coronary
revascularization, was also shown to be particularly appro-
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
ACUTE  Antithrombotic Combination Using
Tirofiban and Enoxaparin trial
CRP  C-reactive protein
GP  glycoprotein
hs-CRP  high-sensitivity C-reactive protein
IL  interleukin
LMWH  low-molecular-weight heparin
MI  myocardial infarction
mRNA  messenger ribonucleic acid
VCAM  vascular cell adhesion molecule
Figure 1. Schematic depiction in sagittal view of inflammation and embolization.
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priate in patients with an abnormal troponin elevation on
admission (17) with GP IIb/IIIa inhibitor therapy as back-
ground therapy. In contrast, clopidogrel did not afford
preferential benefit in the Clopidogrel in Unstable angina to
prevent Recurrent ischemic Events (CURE) trial. In this
case the approximate 20% reduction in death or nonfatal
myocardial infarction (MI) was similar in both groups,
regardless of troponin measurement (18). Of note, abcix-
imab failed to provide benefit in troponin-positive patients
in the Global Use of Strategies To Open occluded arteries
in acute coronary syndromes (GUSTO)-4 trial. In fact, the
observed trend of detrimental outcome demonstrates an
unexpected adverse effect of long (48-h) infusions of abcix-
imab in medically treated patients (19).
Based on the current evidence, platelet GP IIb/IIIa
inhibitors (tirofiban and lamifiban) and LMWHs (enoxapa-
rin or dalteparin), combined with an invasive strategy, have
been shown to be beneficial in patients with elevated
troponin. Therefore, it is vital to measure this biomarker on
admission in patients who present with clinical and electro-
cardiographic evidence of a non–ST-segment elevation
ACS. Although the combined beneficial impact of an
invasive strategy plus LMWH or an invasive strategy plus
small molecule GP IIb/IIIa inhibitor has been fully vali-
dated in two large-scale trials (17,20), there has not yet been
a trial combining all three of these components—GP
IIb/IIIa inhibitor, LMWH, and an invasive strategy.
Combination of LMWH and GP IIb/IIIa inhibi-
tor. There are ongoing large-scale trials designed to evalu-
ate these agents in combination. These include the Superior
Yield of the New strategy of Enoxaparin, Revascularization,
and GlYcoprotein IIb/IIIa inhibitors (SYNERGY), which
compares enoxaparin versus unfractionated heparin, with or
without GP IIb/IIIa inhibitor, and the A to Z trial, which
compares the combination of tirofiban plus unfractionated
heparin versus tirofiban plus enoxaparin. The early data,
which appear encouraging, consist of two randomized pilot
trials: the Antithrombotic Combination Using Tirofiban
and Enoxaparin (ACUTE) I and II, and a subgroup analysis
of the Platelet IIb/IIIa Antagonism for the Reduction of
Acute coronary syndrome Global Organization Network
Figure 2. The survival distribution function curves represent the unad-
justed fraction of survivors as a function of remaining hospitalized patients
at the given time (patients at risk). ECG  electrocardiogram. With
permission from Welch RD, et al. JAMA 2001;286:1977–84, 2002,
American Medical Association.
Figure 3. Risk of mortality in acute coronary syndrome studies. I/T 
troponin I/troponin T; OR  odds ratio. Adapted from data contained in
Heidenreich PA, et al. J Am Coll Cardiol 2001;38:478–85.
Figure 4. (A) Comparison of glycoprotein IIb/IIIa receptor inhibition
trials in patients testing troponin-positive demonstrates marked homoge-
neity. p  0.001 Breslow-Day homogeneity. (B) Clinical outcomes at 14
days for patients treated with enoxaparin versus unfractionated heparin
(UFH) stratified by 0 to 24 h cardiac troponin I (cTnl) results. CI 
confidence interval; CKMB Neg. Pts  creatine kinase-myocardial band-
negative patients; D/MI/UR  death, MI, or urgent revascularization;
GUSTO  Global Use of Strategies To Open occluded arteries in acute
coronary syndromes trial; IIb/IIIa  glycoprotein IIb/IIIa receptor inhib-
itor; PARAGON  Platelet IIb/IIIa Antagonism for the Reduction of
Acute coronary syndrome Global Organization trial; PRISM  Platelet
Receptor Inhibition for Ischemic Syndrome Management trial; RR 
relative risk of the outcome for patients treated with enoxaparin versus
unfractionated heparin. Reprinted with permission from the American
College of Cardiology (J Am Coll Cardiol 2000;36:1812–7).
125SJACC Vol. 41, No. 4 Suppl S Topol
February 19, 2003:123S–129S Decision-Making in Non–ST-Segment Elevation ACS
(PARAGON)-B trial, which allowed the use of LMWH
(21–23). In ACUTE I, an additive effect on antiplatelet
inhibition was demonstrated when enoxaparin and tirofiban
were combined (21). This was extended in ACUTE II for
525 patients randomly assigned to tirofiban plus enoxaparin,
compared with tirofiban plus unfractionated heparin. No
significant or numerical excess in major bleeding or trans-
fusions was associated with the tirofiban/enoxaparin com-
bination (22). In the PARAGON-B trial, almost 600
patients received LMWH rather than unfractionated hep-
arin. Subjects treated with both lamifiban and LMWH had
the lowest death or nonfatal MI rate and no evidence of an
increase in major bleeding (23).
Added to these recent trials are the results of the
Enoxaparin plus TNK-tPA wIth/without GP IIb/IIIa as
REperfusion for STEMI-Thrombolysis In Myocardial In-
farction (ENTIRE-TIMI)-23, which combined enoxaparin
and abciximab with tenecteplase for acute MI reperfusion
therapy (24). Of note, even with fibrinolytic background
therapy, the combination of the LMWH and GP IIb/IIIa
inhibitor was associated with less bleeding than combina-
tions using unfractionated heparin.
Definitive judgments must await the completion of trials
such as the SYNERGY and A to Z, but high-risk patients
such as those with troponin positivity, diabetes, prior MI,
and other risk factors may warrant consideration for the use
of both classes of agents. The original concerns about
bleeding have largely been mitigated, and the only remain-
ing issue is to establish definitive proof of enhanced efficacy
to justify the higher cost of therapy. The issue of safety for
very low incidence adverse events, such as intracerebral
hemorrhage, will be firmly established only when the data
from ongoing large-scale trials become available.
The importance of diabetes mellitus in decision-
making. Roffi et al. (25) recently performed a pooled
analysis of data from all diabetic patients (n  6,750)
enrolled in intravenous platelet GP IIb/IIIa inhibitor trials
and found an important reduction in mortality from 6.2%
(placebo group) to 4.6% in the GP IIb/IIIa inhibitor-
assigned patients (Fig. 5). This 26% reduction in mortality
(p 0.007) was also demonstrated to be a highly significant
treatment by diabetic subgroup interaction (25). The precise
mechanism for this particular benefit among diabetics is not
known. Indeed, the frank survival benefit is distinct from
that in troponin-positive patients associated with reduced
MI incidence. Whether this benefit is related to increased
platelet activation in diabetics, other evidence of heightened
inflammation, or more diffuse atherosclerosis with a pro-
pensity for microvascular obstruction needs further explo-
ration. Even without definition of the mechanism, the data
are convincing enough that the use of GP IIb/IIIa inhibitors
should be strongly considered for diabetic patients present-
ing with ACS.
The importance of inflammatory markers. Beyond rou-
tine testing for troponin, the additive value of tracking
inflammation has been definitively established. Morrow et
al. (26) demonstrated this in the TIMI IIA trial that
indexed prognosis for 14-day mortality to the rapid
troponin-T assay and C-reactive protein (CRP) level (Fig.
6A). In the FRagmin during InStability in Coronary artery
disease (FRISC) trial, Lindahl et al. (27) measured the
incidence of cardiac death at one year and found that the
risk ranged from 0% to 16% among patients who had
elevated troponin and CRP levels (Fig. 6B). A host of other
studies have supported the prognostic value of other inflam-
matory markers, including a simple white blood cell count,
measurement of VCAM, or pregnancy-associated plasma
protein A (28). For patient prognosis, and particularly for
risk of late (one year as opposed to seven days) death,
hs-CRP is the most economical, widely available, and
validated test to date.
Recently, CRP and IL-6 have been shown to be useful
guides to therapy because of their ability to predict which
patients would benefit from an invasive strategy (29).
Glycoprotein IIb/IIIa inhibitors and LMWHs have not yet
been shown to be indexed to CRP levels. However, enox-
aparin’s anti-inflammatory effect may be based on its capa-
bility to lower plasma levels of von Willebrand factor
(30,31). The GP IIb/IIIa inhibitors have been shown to
suppress CRP and other inflammatory markers (32), but
their particular use in patients with an elevated CRP has not
yet been addressed. An important strategy that awaits
testing is the use of medications to lower the CRP level
before coronary revascularization is performed.
The role of thienopyridines to reduce inflamma-
tion. Chew et al. (33) recently demonstrated that clopi-
dogrel treatment before percutaneous coronary intervention
was effective in reducing the level of hs-CRP. This effect
does not seem to occur with low dose aspirin (34), but there
Figure 5. Odds ratio with 95% confidence intervals (CI) and correspond-
ing p values for treatment effect on 30-day mortality among diabetic
patients with acute coronary syndromes. Values to the left of 1.0 indicate
survival benefit of platelet glycoprotein IIb/IIIa inhibition. GUSTO 
Global Use of STrategies to Open occluded arteries in acute coronary
syndromes trial; PARAGON  Platelet IIb/IIIa Antagonism for the
Reduction of Acute coronary syndrome Global Organization Network
trial; PRISM-PLUS  Platelet Receptor inhibition for Ischemic Syn-
drome Management in Patients Limited by Unstable Signs and Symptoms
trial; PURSUIT  Platelet glycoprotein IIb/IIIa in Unstable angina:
Receptor Suppression Using Integrilin Therapy trial. Roffi M, Chew DP,
Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce
mortality in diabetic patients with non–ST-segment elevation acute coro-
nary syndromes. Circulation 2001;104:2767–71. Reproduced with permis-
sion from Lippincott, Williams and Wilkins.
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are synerism effects with the combination of aspirin and
clopidogrel on markers of platelet activation, such as
P-selectin (a proxy for a heightened state of inflammation)
(35). With the recent CURE trial (18) validating the use of
combined clopidogrel and aspirin in patients with non–ST-
segment elevation acute ischemic heart disease, there is now
mechanistic support for the significant benefit documented
in that trial.
Recommendations based on a clinical and pathophysio-
logic approach. As we await data from ongoing trials and
mechanistic studies, it seems reasonable to assay both
troponin and hs-CRP in all patients with ACS. If the
hs-CRP assay is unavailable, a white blood count, at least, is
recommended. The clinical risk profile should be estab-
lished, noting a history of diabetes, age, prior history of
heart failure or stroke, renal impairment, and ST depression
on the electrocardiogram on presentation or at repeat
assessment. Prior use of aspirin appears to be another
important risk feature (36,37).
For patients at highest risk—those with elevated troponin
and CRP levels, an ST depression on the electrocardiogram,
and diabetes—the “maximum” therapy is warranted. Aspi-
rin, beta-blockers, nitrates, and a statin should be given, and
clopidogrel, enoxaparin, a GP IIb/IIIa inhibitor, plus an
invasive strategy should be considered. The timing of the
first dose of clopidogrel (loading, 300 mg) needs to be
determined on the basis of whether the patient is likely to
undergo emergency coronary artery bypass surgery. The risk
of significant bleeding is at least 60% higher among patients
who have received both clopidogrel and aspirin compared
with those given aspirin alone at the time of bypass surgery
when the surgery is performed within five days of clopi-
dogrel dosing (18). Accordingly, clopidogrel can be initiated
in the emergency room setting, if early coronary artery
Figure 6. (A) (Left) Risk stratification by C-reactive protein (CRP) (mg/dl) and rapid cardiac troponin T (cTnT) assay status expressed as 14-day mortality
rate by CRP and rapid cTnT result. Early positive rapid cTnT assays are those that could be read positive by 10 min. Trend evaluated by chi-squared
test. (Right) Mortality rate at 14 days by CRP and rapid cTnT assay status. Early positive rapid assays for cTnT are those for which the red line appeared
by 10 min, with a “negative” test in this category including both negative and late positive rapid cTnT results. C-reactive protein 1.55 mg/dl is
considered a positive test. “Test Positive” in the category “CRP 1.55 mg/dl and Rapid cTnT early positive” requires both tests to be positive, with a
“negative” test in this category representing all other combinations. With permission from Morrow DA et al. J Am Coll Cardiol 1998;31:1460–5. (B)
Incidence of death from cardiac causes at two years in the FRagmin during InStability in Coronary artery disease trial (FRISC) according to the presence
or absence of ST-segment depression on the admission electrocardiogram and the maximal troponin T (TnT) levels during the first 24 h after enrollment
and to the CRP levels and the maximal TnT levels. Neg  negative; Pos  positive. With permission from Lindahl B, et al. N Engl J Med
2000;343:1139–47.
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bypass graft surgery is not anticipated, or deferred until an
angiogram rules out surgical anatomy.
The decision to implement a GP IIb/IIIa inhibitor for
such high-risk patients is simply a matter of “when” and not
“if,” unless there is a bleeding diathesis or if the coronary
anatomy demonstrates lack of suitability for percutaneous
coronary revascularization. In high-risk patients, starting a
small molecule GP IIb/IIIa inhibitor in the emergency
room (either tirofiban or eptifibatide) is a reasonable strat-
egy with early angiography performed the following morn-
ing. Alternatively, the patient can undergo acute angiogra-
phy, and the GP IIb/IIIa inhibitor abciximab can be
reserved for the patient who proves to be suitable for
percutaneous coronary revascularization. This agent has
been shown to be superior to tirofiban, especially in ACS
patients undergoing stenting, at the doses tested in the
comparative large-scale do Tirofiban And Reopro Give
similar Efficacy Trial (TARGET) (38). There are no
definitive data comparing eptifibatide with abciximab. Until
data become available from trials of tirofiban at increased
doses, or eptifibatide in head-to-head trials, abciximab
should be considered the agent of choice in patients with
ACS undergoing percutaneous coronary intervention.
The only LMWH proven to be superior to unfraction-
ated heparin in the setting of ACS is enoxaparin. The sole
remaining issue for large-scale application of this agent has
been its use during percutaneous coronary revascularization
procedures, as there has been concern regarding the inability
to monitor the level of anticoagulation during the proce-
dure. This concern appears to be addressed by recent studies
using an empiric approach based on the timing of the last
dose of enoxaparin to the performance of the coronary
intervention. More data will be forthcoming from trials such
as SYNERGY and A to Z. In high-risk patients presenting
at hospitals without emergency cardiac catheterization fa-
cilities, the use of enoxaparin to replace unfractionated
heparin is supported by the results of two trials (39,40).
For intermediate- and low-risk patients, a “sliding-scale”
approach may be best. Decisions about the three classes of
antithrombotics—LMWHs, GP IIb/IIIa inhibitors, and
the thienopyridines—along with whether to adopt an early
invasive strategy, should be made on an individual basis.
There will undoubtedly be continued refinement of our
approach, both with respect to optimal use of biomarkers
and the implementation of the various pharmacologic and
revascularization approaches. It is indeed striking, however,
that our increased insight about the propensity for inflam-
mation and embolization has already markedly affected our
routine approach to patients with ACS.
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